|
Name |
Methyl 3-methylpentanoate
|
Molecular Formula | C7H14O2 | |
IUPAC Name* |
methyl 3-methylpentanoate
|
|
SMILES |
CCC(C)CC(=O)OC
|
|
InChI |
InChI=1S/C7H14O2/c1-4-6(2)5-7(8)9-3/h6H,4-5H2,1-3H3
|
|
InChIKey |
FHASOOYJUZKVFW-UHFFFAOYSA-N
|
|
Synonyms |
Methyl 3-methylpentanoate; Methyl 3-methylvalerate; 2177-78-8; METHYL3-METHYLPENTANOATE; Valeric acid, 3-methyl-, methyl ester; Pentanoic acid, 3-methyl-, methyl ester; Pentanoic acid,3-methyl-,methyl ester; methyl-3-methyl pentanoate; Methyl .beta.-methylvalerate; SCHEMBL5711131; DTXSID70334182; 3-Methylvaleric acid methyl ester; 3-Methylvaleric acid, methyl ester; Methyl 3-methylvalerate, >=97.0%; DB-066628; FT-0710427; J-014282; 2,2-[1,4-PHENYLENEBIS(METHYLENE)]BIS-1H-BENZOIMIDAZOLE
|
|
CAS | 2177-78-8 | |
PubChem CID | 519891 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 130.18 | ALogp: | 2.4 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 26.3 | Aromatic Rings: | 0 |
Heavy Atoms: | 9 | QED Weighted: | 0.547 |
Caco-2 Permeability: | -4.292 | MDCK Permeability: | 0.00002950 |
Pgp-inhibitor: | 0.006 | Pgp-substrate: | 0.004 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.005 |
30% Bioavailability (F30%): | 0.18 |
Blood-Brain-Barrier Penetration (BBB): | 0.998 | Plasma Protein Binding (PPB): | 31.73% |
Volume Distribution (VD): | 0.815 | Fu: | 67.60% |
CYP1A2-inhibitor: | 0.641 | CYP1A2-substrate: | 0.444 |
CYP2C19-inhibitor: | 0.212 | CYP2C19-substrate: | 0.863 |
CYP2C9-inhibitor: | 0.112 | CYP2C9-substrate: | 0.38 |
CYP2D6-inhibitor: | 0.008 | CYP2D6-substrate: | 0.284 |
CYP3A4-inhibitor: | 0.022 | CYP3A4-substrate: | 0.268 |
Clearance (CL): | 10.923 | Half-life (T1/2): | 0.847 |
hERG Blockers: | 0.009 | Human Hepatotoxicity (H-HT): | 0.13 |
Drug-inuced Liver Injury (DILI): | 0.202 | AMES Toxicity: | 0.008 |
Rat Oral Acute Toxicity: | 0.039 | Maximum Recommended Daily Dose: | 0.049 |
Skin Sensitization: | 0.807 | Carcinogencity: | 0.196 |
Eye Corrosion: | 0.971 | Eye Irritation: | 0.982 |
Respiratory Toxicity: | 0.224 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000225 | 0.593 | D0ZK8H | 0.387 | ||||
ENC000416 | 0.484 | D0OL6O | 0.289 | ||||
ENC000241 | 0.438 | D02KBD | 0.255 | ||||
ENC000819 | 0.417 | D0G8SQ | 0.250 | ||||
ENC000182 | 0.407 | D07ZTO | 0.250 | ||||
ENC001788 | 0.400 | D04MWJ | 0.250 | ||||
ENC000235 | 0.382 | D00WUF | 0.244 | ||||
ENC000382 | 0.379 | D0K3LW | 0.237 | ||||
ENC001288 | 0.378 | D0I5HV | 0.233 | ||||
ENC000833 | 0.368 | D0U7BW | 0.231 |